echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Shangjian Bio-CD38/CD47 double antibody was approved for clinical use in the U.S.

    Shangjian Bio-CD38/CD47 double antibody was approved for clinical use in the U.S.

    • Last Update: 2022-01-15
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    ArticleMedicine Guanlan

    On November 22, Suntech announced that its self-developed world's first targeting CD38/CD47 double antibody SG2501 has been approved by the US FDA for clinical research


    CD38 molecule is a single-chain type II transmembrane glycoprotein, which is widely expressed in hematopoietic cells and non-hematopoietic cell lines, and has many complex and unique biological characteristics and functions


    CD47 is a glycoprotein widely expressed on the surface of a variety of cancer cells.


    According to the press release, SG2501 is an anti-CD38/CD47 double antibody developed based on the BIMA double antibody platform of Suntech.


    It is worth mentioning that, based on the BIMA double antibody platform, Sunkin Bio has also developed a number of "1+1>2" double antibody projects, two of which have been approved for clinical use


    Reference

    [1] Shangjian Biological announced that the world’s first bi-antibody of its kind, SG2501, was approved by the FDA for clinical use.


    [2]Sumgen Bio Official Website.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.